On November 13, Glonghui reported that shenzhen neptunus bioengineering (000078.SZ) stated in its investor relations that the medical device distribution business has a higher gross profit level compared to the pharmaceutical distribution business and is relatively less affected by policies. Therefore, the medical device business is one of the key sectors for the company's development, with the current medical device business scale at about 10 billion. In the future, the company will expand the scale of its medical device agency and direct sales business, aiming to transform from a market agent to a company with foreign brand agency rights, introducing advanced technologies and high-quality products from foreign brands to further enhance the company's medical device business level and market competitiveness.